摘要Background Hypertension combined with dyslipidemia is the main cause of cerebrovascular and cardiovascu-lar accidents in elderly patients,and actively controlling blood pressure and lipid levels is the best way to reduce the risk of cardiovascular accidents and death.This study focused on the clinical pharmaceutical analysis of combined therapy with amlodipine benzenesulfonate and atorvastatin calcium for elderly patients with hypertension and dys-lipidemia.Methods A total of 292 elderly patients with hypertension and dyslipidemia from August 2022 to Feb-ruary 2023 were selected and grouped according to random number table method,and evenly assigned to control group(n=146)and observation group(n=146).Control group was treated with amlodipine besylate,and observa-tion group was treated with combined therapy with amlodipine benzenesulfonate and atorvastatin calcium.The ef-fects and adverse reactions of the two groups were compared,and the changes of blood pressure and lipid indexes before and after treatment were also compared.Results The total effective rate of observation group was higher than that of control group,the difference was significant(P＜0.05).There was no significant difference in the inci-dence of adverse reactions between the two groups(P＞0.05).No significant differences were found in systolic blood pressure,diastolic blood pressure,total cholesterol and triglyceride between the two groups before treatment(P＞0.05).While after treatment,the level of systolic blood pressure,diastolic blood pressure,total cholesterol and triglyceride in the observation group were lower than those in the control group(P＜0.05).Conclusions The com-bination therapy with amlodipine benzenesulfonate and atorvastatin calcium is effective and safe,improving blood pressure and lipid levels in patients with hypertension and dyslipidemia,and can be widely applied to elderly pa-tients with hypertension and dyslipidemia.[S Chin J Cardiol 2024;25(1):38-43]